drugset / Trial / NCT01163643

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

NCT01163643

Phase 2 Completed 356 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.

Timeline

Start
2010-07
Primary completion
2011-06
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mapracorat Small molecule 0.3 % Other
Subject Mapracorat Small molecule 1 % Other
Subject Mapracorat Small molecule 2 % Other

Indications